SCHEMBL2094492

SCHEMBL2094492

OCOc1ccc(Br)cc1F

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.47
POLB P06746 1/20 0.47
PKM P14618 1/20 0.47
AAK1 Q2M2I8 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
GAA P10253 1/20 0.42
USP28 Q96RU2 1/20 0.41
PTGDR2 Q9Y5Y4 2/20 0.41
NSD2 O96028 1/20 0.41
NSD3 Q9BZ95 1/20 0.41
DGAT1 O75907 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SLC6A4 P31645 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3189588 0.85 KDM4E (0.45) KDM4EPOLBPKMAAK1L3MBTL1
SCHEMBL15300823 0.83 KDM4E (0.44) KDM4EPOLBPKMAAK1L3MBTL1
SCHEMBL15677337 0.82 KDM4E (0.42) KDM4EPOLBPKMAAK1L3MBTL1
SCHEMBL2094490 0.80 KDM4E (0.44) KDM4EPOLBPKMAAK1L3MBTL1
SCHEMBL1509935 0.80 HPGD (0.51) AAK1L3MBTL1GAARAB9ASLC6A4
SCHEMBL12144437 0.79 AAK1 (0.55) KDM4EPOLBPKMAAK1L3MBTL1
SCHEMBL1824099 0.78 NSD2 (0.46) KDM4EPOLBPKMAAK1L3MBTL1
SCHEMBL7769950 0.78 NSD2 (0.46) KDM4EPOLBPKMAAK1L3MBTL1
SCHEMBL3203774 0.78 PTGDR2 (0.64) KDM4EPOLBPKML3MBTL1PTGDR2
SCHEMBL14774842 0.78 USP28 (0.50) KDM4EPOLBPKML3MBTL1USP28

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023029380-A1 NOVEL ARYL ETHER SUBSTITUTED HETEROCYCLIC COMPOUND AS GLP1R AGONIST 杭州德睿智药科技有限公司 2023-03-09 WO disclosed
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 KDM4E 4578/4885POLB 757/4885PKM 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.